| Trial ID: | L5544 |
| Source ID: | NCT04676906
|
| Associated Drug: |
Nnc0113-6861
|
| Title: |
A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy Volunteers|Type 2 Diabetes
|
| Interventions: |
DRUG: NNC0113-6861|DRUG: NNC0113-6860|DRUG: NNC0113-6891
|
| Outcome Measures: |
Primary: The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds, hours, From time of first dosing (Day 1) until Day 64 |
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-11-26
|
| Completion Date: |
2021-04-28
|
| Results First Posted: |
|
| Last Update Posted: |
2023-04-27
|
| Locations: |
Novo Nordisk Investigational Site, Groningen, 9728 NZ, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT04676906
|
